Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 16/20 | 1.00 |
| ▸ | KIF5B | P33176 | 11/20 | 1.00 |
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 0.66 |
| ▸ | EGFR | P00533 | 2/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.65 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.65 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.65 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7076160 | 0.90 | RET (1.00) | RETKIF5BKDRFLT1EGFR | |
| SCHEMBL16760418 | 0.89 | RET (1.00) | RETKIF5BKDRFLT1EGFR | |
| SCHEMBL16785515 | 0.89 | RET (1.00) | RETKIF5BKDRFLT1EGFR | |
| SCHEMBL16760410 | 0.88 | RET (1.00) | RETKIF5BKDRFLT1EGFR | |
| SCHEMBL16760370 | 0.88 | RET (1.00) | RETKIF5BKDRFLT1EGFR | |
| Hydrochloric Acid SCHEMBL16760376 | 0.88 | RET (0.98) | RETKIF5BKDRFLT1EGFR | |
| SCHEMBL21225145 | 0.88 | RET (0.78) | RETKIF5BKDRFLT1EGFR | |
| Hydrochloric Acid SCHEMBL16760380 | 0.87 | RET (0.98) | RETKIF5BKDRFLT1EGFR | |
| SCHEMBL16760419 | 0.86 | RET (1.00) | RETKIF5BKDRFLT1EGFR | |
| SCHEMBL16760445 | 0.85 | RET (1.00) | RETKIF5BKDRFLT1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038049-B2 | Haloanilino quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2005-04-07 | — | — | US | disclosed |
| US-6638939-B2 | Anticancer agents | PARKER HUGHES INSTITUTE | 2003-10-28 | — | — | US | disclosed |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2002-08-15 | — | — | US | disclosed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | RET 1370/4885KIF5B 3899/4885KDR 3004/4885 |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | CMA1, MAST3, MAST1 | RET 2800/4885KIF5B 3284/4885KDR 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.